Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Neoplasms
  • Sirolimus

abstract

  • mCRM-based dose escalation using real-time pharmacodynamic assessment was feasible. However, the selected pharmacodynamic end point did not correlate with dose. Toxicity ultimately drove dose selection. Rapamycin is a well-tolerated and active oral anticancer agent.

publication date

  • September 18, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2654371

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.16.2347

PubMed ID

  • 18757332

Additional Document Info

start page

  • 4172

end page

  • 9

volume

  • 26

number

  • 25